Wall Street brokerages predict that Masimo Co. (NASDAQ:MASI) will post $208.01 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Masimo’s earnings. The highest sales estimate is $209.70 million and the lowest is $205.45 million. Masimo reported sales of $192.93 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.8%. The firm is expected to issue its next earnings results on Wednesday, August 1st.
On average, analysts expect that Masimo will report full year sales of $843.80 million for the current financial year, with estimates ranging from $837.00 million to $846.29 million. For the next financial year, analysts expect that the company will post sales of $890.94 million per share, with estimates ranging from $887.25 million to $897.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Masimo.
Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.06. The business had revenue of $212.90 million during the quarter, compared to the consensus estimate of $205.65 million. Masimo had a return on equity of 23.14% and a net margin of 15.99%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.57 earnings per share.
Several brokerages have recently issued reports on MASI. ValuEngine downgraded Masimo from a “buy” rating to a “hold” rating in a research report on Thursday, June 7th. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 8th. Zacks Investment Research downgraded Masimo from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. BTIG Research reissued a “buy” rating and set a $100.00 target price on shares of Masimo in a report on Thursday, May 3rd. Finally, Piper Jaffray Companies boosted their target price on Masimo to $94.00 and gave the stock a “neutral” rating in a report on Wednesday, May 2nd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $101.17.
Shares of NASDAQ MASI traded up $0.62 during midday trading on Monday, hitting $101.54. 412,243 shares of the company’s stock were exchanged, compared to its average volume of 507,466. The company has a market cap of $5.24 billion, a PE ratio of 41.44, a P/E/G ratio of 2.41 and a beta of 0.95. Masimo has a twelve month low of $80.69 and a twelve month high of $102.32.
In related news, insider Jon Coleman sold 29,303 shares of the business’s stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $87.50, for a total transaction of $2,564,012.50. Following the sale, the insider now owns 20,504 shares of the company’s stock, valued at $1,794,100. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $86.02, for a total value of $172,040.00. Following the sale, the director now directly owns 66,249 shares in the company, valued at approximately $5,698,738.98. The disclosure for this sale can be found here. In the last three months, insiders have sold 137,203 shares of company stock worth $12,640,110. 12.60% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. USA Mutuals Advisors Inc. bought a new position in shares of Masimo in the fourth quarter valued at $110,000. SeaCrest Wealth Management LLC bought a new position in shares of Masimo in the fourth quarter valued at $116,000. Advisors Preferred LLC bought a new position in shares of Masimo in the fourth quarter valued at $158,000. Campbell & CO Investment Adviser LLC bought a new position in shares of Masimo in the first quarter valued at $202,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Masimo in the first quarter valued at $203,000. 83.77% of the stock is currently owned by institutional investors.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Get a free copy of the Zacks research report on Masimo (MASI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.